


**METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS (MASH)**

Enhanced Liver Fibrosis (ELF™) Test

Understanding a person's risk of progression to end-stage liver disease can lead to better patient management and significantly improved outcomes.

The prevalence metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD) in the United States is reported to be between 10% and 30%, and the pooled overall global prevalence of MASLD is estimated to be greater than 25%.^{1,2} MASLD may range from a non-serious condition called fatty liver to a potentially serious condition called metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH).



Estimated global
prevalence of MASLD



- ✓ **More accurate results.**
- ✓ **Fewer invasive procedures.**
- ✓ **Better outcomes.**

MASLD is the most common cause of chronic liver disease in developed countries, largely due to the increased prevalence of comorbidities such as obesity and Type 2 diabetes. A percentage of patients with MASH and liver fibrosis will eventually progress to cirrhosis and/or hepatocellular carcinoma. In fact, MASH is expected to become the leading cause of liver transplantation in the United States in the next few years.³⁻⁵

Therefore, there is an urgent need for a noninvasive prognostic test for identifying patients with MASH who are at increased risk of developing end-stage liver disease so they can be treated aggressively to prevent disease progression.

The Enhanced Liver Fibrosis (ELF™) blood test is a simple, accurate, noninvasive test that provides a numeric score for use in patients known to have advanced liver fibrosis. It is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to MASH in order to assess the likelihood of progression to cirrhosis and liver-related clinical events.⁶

The ELF™ test measures three direct markers of liver fibrosis: hyaluronic acid (HA), Type III procollagen peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). The results of these three biomarkers are integrated through an automated algorithm to provide a score that assesses the likelihood of progression to cirrhosis and liver-related clinical events.

For early treatment and prevention of progression to late-stage liver disease, we can help.



MASH: Progression of a potentially life-threatening disease

ELF Score	Risk of Progression
<9.80	Lower Risk
9.80 - 11.29	Mid Risk
>11.29	Higher Risk

Test Information

Test Name	Test No.	Specimen	Container	Storage
Enhanced Liver Fibrosis (ELF™) Test	550659	2.5 mL Serum	Gel-barrier tube or red-top tube	Frozen (preferred) or refrigerated

LOINC® Map

Order Code	Order Code Name	Order LOINC	Result Code	Result Code Name	UofM	Result LOINC
550659	Enhanced Liver Fibrosis (ELF)	88055-9	550661	ELF™ Score		48795-9

References

- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther.* 2011.
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology.* 2016.
- Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. *Journal of hepatology.* 2019;70(3):531-544.
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* 2018;67(1):328-357.
- Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. *Nature reviews Gastroenterology & Hepatology.* 2019;16(6):377-386.
- ADVIA Centaur® Enhanced Liver Fibrosis (ELF) [package insert]. Tarrytown, NY. Siemens Healthcare Diagnostics Inc. Rev. 01, 2021-08.

For more information about ELF™ and how it can benefit your patients, contact your Labcorp sales representative. For more information on MASH and MASLD, visit [Labcorp.com/NASH-providers](https://www.labcorp.com/NASH-providers).

